XML 75 R51.htm IDEA: XBRL DOCUMENT
v3.20.2

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 28, 2020 | Jun. 30, 2019 | Jun. 28, 2020 | Jun. 30, 2019
Sales by segment of business |  |  |  |
Sales to customers | $ 18,336 | $ 20,562 | $ 39,027 | $ 40,583
Percent Change (as a percent) | (10.80%) |  | (3.80%) |
U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 9,539 | 10,403 | $ 20,238 | 20,532
Percent Change (as a percent) | (8.30%) |  | (1.40%) |
International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 8,797 | 10,159 | $ 18,789 | 20,051
Percent Change (as a percent) | (13.40%) |  | (6.30%) |
Consumer Health* |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,296 | 3,544 | $ 6,921 | $ 6,862
Percent Change (as a percent) | (7.00%) |  |  | 0.90%
Consumer Health* | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,557 | 1,537 | 3,297 | $ 2,975
Percent Change (as a percent) | 1.30% |  |  | 10.80%
Consumer Health* | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,739 | 2,007 | 3,624 | $ 3,887
Percent Change (as a percent) | (13.40%) |  |  | (6.80%)
Consumer Health* | Baby Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 356 | 443 | 717 | $ 837
Percent Change (as a percent) | (19.70%) |  |  | (14.30%)
Consumer Health* | Baby Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 96 | 99 | $ 188 | $ 186
Percent Change (as a percent) | (3.50%) |  | 1.20% |
Consumer Health* | Baby Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 260 | 344 | $ 529 | $ 651
Percent Change (as a percent) | (24.30%) |  |  | (18.70%)
Consumer Health* | Oral Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 397 | 389 | 792 | $ 756
Percent Change (as a percent) | 2.20% |  |  | 4.80%
Consumer Health* | Oral Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 170 | 155 | 346 | $ 306
Percent Change (as a percent) | 9.70% |  |  | 12.90%
Consumer Health* | Oral Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 227 | 234 | 446 | $ 450
Percent Change (as a percent) | (2.80%) |  |  | (0.80%)
Consumer Health* | OTC |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,149 | 1,064 | 2,497 | $ 2,151
Percent Change (as a percent) | 7.90% |  |  | 16.10%
Consumer Health* | OTC | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 627 | 484 | 1,316 | $ 991
Percent Change (as a percent) | 29.60% |  |  | 32.80%
Consumer Health* | OTC | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 522 | 580 | 1,181 | $ 1,160
Percent Change (as a percent) | (10.10%) |  |  | 1.80%
Consumer Health* | Skin Health/Beauty |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,007 | 1,202 | 2,124 | $ 2,292
Percent Change (as a percent) | (16.20%) |  |  | (7.30%)
Consumer Health* | Skin Health/Beauty | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 536 | 663 | 1,195 | $ 1,251
Percent Change (as a percent) | (19.20%) |  |  | (4.50%)
Consumer Health* | Skin Health/Beauty | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 471 | 539 | 929 | $ 1,041
Percent Change (as a percent) | (12.50%) |  |  | (10.70%)
Consumer Health* | Women's Health |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 202 | 253 | 434 | $ 478
Percent Change (as a percent) | (20.10%) |  |  | (9.30%)
Consumer Health* | Women's Health | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 3 | 7 | $ 6
Percent Change (as a percent) | (2.90%) |  |  | 14.30%
Consumer Health* | Women's Health | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 199 | 250 | 427 | $ 472
Percent Change (as a percent) | (20.40%) |  |  | (9.60%)
Consumer Health* | Wound Care/Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 185 | 193 | 356 | $ 348
Percent Change (as a percent) | (4.00%) |  |  | 2.60%
Consumer Health* | Wound Care/Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 126 | 132 | 245 | $ 234
Percent Change (as a percent) | (4.70%) |  |  | 4.70%
Consumer Health* | Wound Care/Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 59 | 61 | 111 | $ 114
Percent Change (as a percent) | (2.40%) |  |  | (1.90%)
PHARMACEUTICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 10,752 | 10,529 | $ 21,886 | $ 20,773
Percent Change (as a percent) | 2.10% |  | 5.40% |
PHARMACEUTICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6,120 | 5,783 | $ 12,181 | 11,365
Percent Change (as a percent) | 5.80% |  | 7.20% |
PHARMACEUTICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,632 | 4,746 | $ 9,705 | 9,408
Percent Change (as a percent) | (2.40%) |  | 3.20% |
PHARMACEUTICAL | Immunology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,523 | 3,466 | $ 7,161 | 6,717
Percent Change (as a percent) | 1.60% |  | 6.60% |
PHARMACEUTICAL | Immunology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,362 | 2,379 | $ 4,772 | 4,542
Percent Change (as a percent) | (0.70%) |  | 5.10% |
PHARMACEUTICAL | Immunology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,161 | 1,087 | $ 2,389 | 2,175
Percent Change (as a percent) | 6.80% |  | 9.80% |
PHARMACEUTICAL | Immunology | REMICADE® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 935 | 1,107 | $ 1,925 | 2,209
Percent Change (as a percent) | (15.50%) |  | (12.90%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 593 | 801 | $ 1,218 | 1,575
Percent Change (as a percent) | (25.80%) |  | (22.70%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 133 | 62 | $ 243 | 138
Percent Change (as a percent) |  |  | 75.70% |
PHARMACEUTICAL | Immunology | REMICADE® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 208 | 244 | $ 464 | 496
Percent Change (as a percent) | (14.50%) |  | (6.40%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 546 | 563 | $ 1,075 | 1,087
Percent Change (as a percent) | (3.00%) |  | (1.10%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 256 | 281 | $ 528 | 544
Percent Change (as a percent) | (8.70%) |  | (2.90%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 289 | 282 | $ 547 | 543
Percent Change (as a percent) | 2.60% |  | 0.80% |
PHARMACEUTICAL | Immunology | STELARA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,697 | 1,558 | $ 3,516 | 2,963
Percent Change (as a percent) | 8.90% |  | 18.70% |
PHARMACEUTICAL | Immunology | STELARA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,138 | 1,058 | $ 2,355 | 1,940
Percent Change (as a percent) | 7.50% |  | 21.40% |
PHARMACEUTICAL | Immunology | STELARA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 558 | 499 | $ 1,161 | 1,022
Percent Change (as a percent) | 11.90% |  | 13.60% |
PHARMACEUTICAL | Immunology | TREMFYA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 342 | 235 | $ 638 | 452
Percent Change (as a percent) | 45.40% |  | 41.10% |
PHARMACEUTICAL | Immunology | TREMFYA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 241 | 176 | $ 428 | 344
Percent Change (as a percent) | 36.70% |  | 24.40% |
PHARMACEUTICAL | Immunology | TREMFYA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 101 | 59 | $ 210 | 108
Percent Change (as a percent) | 71.00% |  | 94.00% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 3 | $ 6 | 6
Percent Change (as a percent) | 11.80% |  | 2.70% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 3 | $ 6 | 6
Percent Change (as a percent) | 11.80% |  | 2.70% |
PHARMACEUTICAL | Infectious Diseases |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 878 | 862 | $ 1,798 | 1,708
Percent Change (as a percent) | 1.90% |  | 5.30% |
PHARMACEUTICAL | Infectious Diseases | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 416 | 387 | $ 852 | 744
Percent Change (as a percent) | 7.40% |  | 14.50% |
PHARMACEUTICAL | Infectious Diseases | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 463 | 475 | $ 946 | 964
Percent Change (as a percent) | (2.50%) |  | (1.80%) |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 256 | 210 | $ 480 | 421
Percent Change (as a percent) | 22.20% |  | 14.10% |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 10 | 12 | $ 22 | 24
Percent Change (as a percent) | (14.00%) |  | (6.90%) |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 246 | 198 | $ 458 | 397
Percent Change (as a percent) | 24.50% |  | 15.40% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 510 | 535 | $ 1,089 | 1,058
Percent Change (as a percent) | (4.70%) |  | 2.90% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 379 | 344 | $ 775 | 659
Percent Change (as a percent) | 10.50% |  | 17.70% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 130 | 191 | $ 314 | 399
Percent Change (as a percent) | (32.00%) |  | (21.40%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 113 | 117 | $ 229 | 229
Percent Change (as a percent) | (4.20%) |  | (0.20%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 25 | 31 | $ 54 | 61
Percent Change (as a percent) | (18.70%) |  | (11.20%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 87 | 86 | $ 174 | 168
Percent Change (as a percent) | 1.00% |  | 3.80% |
PHARMACEUTICAL | Neuroscience |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,587 | 1,538 | $ 3,245 | 3,167
Percent Change (as a percent) | 3.20% |  | 2.50% |
PHARMACEUTICAL | Neuroscience | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 778 | 664 | $ 1,526 | 1,387
Percent Change (as a percent) | 17.40% |  | 10.10% |
PHARMACEUTICAL | Neuroscience | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 809 | 875 | $ 1,719 | 1,780
Percent Change (as a percent) | (7.60%) |  | (3.50%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 149 | 137 | $ 320 | 351
Percent Change (as a percent) | 8.70% |  | (8.90%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 55 | 15 | $ 107 | 112
Percent Change (as a percent) |  |  | (4.20%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 94 | 123 | $ 212 | 239
Percent Change (as a percent) | (23.00%) |  | (11.00%) |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 879 | 818 | $ 1,762 | 1,608
Percent Change (as a percent) | 7.50% |  | 9.50% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 576 | 506 | $ 1,120 | 989
Percent Change (as a percent) | 13.80% |  | 13.20% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 303 | 312 | $ 642 | 619
Percent Change (as a percent) | (2.80%) |  | 3.70% |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 153 | 182 | $ 323 | 361
Percent Change (as a percent) | (15.90%) |  | (10.50%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 74 | 81 | $ 150 | 158
Percent Change (as a percent) | (9.30%) |  | (4.90%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 79 | 101 | $ 173 | 203
Percent Change (as a percent) | (21.20%) |  | (14.90%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 406 | 401 | $ 841 | 847
Percent Change (as a percent) | 1.20% |  | (0.70%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 75 | 62 | $ 150 | 128
Percent Change (as a percent) | 21.50% |  | 16.80% |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 331 | 340 | $ 691 | 719
Percent Change (as a percent) | (2.50%) |  | (3.90%) |
PHARMACEUTICAL | Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,791 | 2,697 | $ 5,804 | 5,215
Percent Change (as a percent) | 3.50% |  | 11.30% |
PHARMACEUTICAL | Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,181 | 1,013 | $ 2,356 | 1,975
Percent Change (as a percent) | 16.60% |  | 19.30% |
PHARMACEUTICAL | Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,609 | 1,684 | $ 3,448 | 3,240
Percent Change (as a percent) | (4.40%) |  | 6.40% |
PHARMACEUTICAL | Oncology | DARZALEX® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 901 | 774 | $ 1,838 | 1,403
Percent Change (as a percent) | 16.30% |  | 31.00% |
PHARMACEUTICAL | Oncology | DARZALEX® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 492 | 369 | $ 955 | 721
Percent Change (as a percent) | 32.90% |  | 32.30% |
PHARMACEUTICAL | Oncology | DARZALEX® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 409 | 405 | $ 883 | 682
Percent Change (as a percent) | 1.20% |  | 29.60% |
PHARMACEUTICAL | Oncology | ERLEADA [Member] |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 170 | 69 | $ 313 | 130
PHARMACEUTICAL | Oncology | ERLEADA [Member] | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 136 | 62 | 255 | 120
PHARMACEUTICAL | Oncology | ERLEADA [Member] | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 33 | 7 | 57 | 10
PHARMACEUTICAL | Oncology | IMBRUVICA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 949 | 831 | $ 1,980 | 1,615
Percent Change (as a percent) | 14.10% |  | 22.60% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 447 | 367 | $ 879 | 716
Percent Change (as a percent) | 21.50% |  | 22.60% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 502 | 463 | $ 1,101 | 898
Percent Change (as a percent) | 8.30% |  | 22.60% |
PHARMACEUTICAL | Oncology | VELCADE® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 98 | 224 | $ 206 | 487
Percent Change (as a percent) | (56.10%) |  | (57.70%) |
PHARMACEUTICAL | Oncology | VELCADE® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Oncology | VELCADE® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 98 | 224 | $ 206 | 487
Percent Change (as a percent) | (56.10%) |  | (57.70%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 568 | 698 | $ 1,258 | 1,377
Percent Change (as a percent) | (18.60%) |  | (8.60%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 87 | 198 | $ 226 | 383
Percent Change (as a percent) | (55.60%) |  | (40.90%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 480 | 500 | $ 1,032 | 994
Percent Change (as a percent) | (3.90%) |  | 3.80% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 106 | 101 | $ 210 | 203
Percent Change (as a percent) | 5.50% |  | 3.40% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 20 | 16 | $ 42 | 34
Percent Change (as a percent) | 22.90% |  | 21.40% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 87 | 85 | $ 169 | 169
Percent Change (as a percent) | 2.20% |  | (0.30%) |
PHARMACEUTICAL | Pulmonary Hypertension |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 789 | 690 | $ 1,534 | 1,346
Percent Change (as a percent) | 14.20% |  | 13.90% |
PHARMACEUTICAL | Pulmonary Hypertension | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 545 | 439 | $ 1,031 | 869
Percent Change (as a percent) | 24.20% |  | 18.70% |
PHARMACEUTICAL | Pulmonary Hypertension | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 243 | 251 | $ 503 | 477
Percent Change (as a percent) | (3.30%) |  | 5.30% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 406 | 348 | $ 795 | 654
Percent Change (as a percent) | 16.50% |  | 21.60% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 256 | 203 | $ 485 | 375
Percent Change (as a percent) | 26.10% |  | 29.30% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 150 | 146 | $ 310 | 279
Percent Change (as a percent) | 3.00% |  | 11.20% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 282 | 203 | $ 532 | 401
Percent Change (as a percent) | 39.00% |  | 32.70% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 254 | 175 | $ 466 | 351
Percent Change (as a percent) | 44.50% |  | 32.60% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 28 | 28 | $ 66 | 50
Percent Change (as a percent) | 4.00% |  | 33.60% |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER PULMONARY HYPERTENSION |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 101 | 140 | $ 207 | 292
Percent Change (as a percent) | (27.50%) |  | (29.00%) |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER PULMONARY HYPERTENSION | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 37 | 61 | $ 81 | 143
Percent Change (as a percent) | (40.20%) |  | (43.50%) |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER PULMONARY HYPERTENSION | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 64 | 78 | $ 126 | 149
Percent Change (as a percent) | (17.60%) |  | (15.10%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,184 | 1,275 | $ 2,344 | 2,620
Percent Change (as a percent) | (7.10%) |  | (10.50%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 837 | 902 | $ 1,643 | 1,849
Percent Change (as a percent) | (7.20%) |  | (11.10%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 347 | 373 | $ 701 | 771
Percent Change (as a percent) | (7.00%) |  | (9.10%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 559 | 549 | $ 1,086 | 1,091
Percent Change (as a percent) | 1.70% |  | (0.50%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 559 | 549 | $ 1,086 | 1,091
Percent Change (as a percent) | 1.70% |  | (0.50%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 179 | 177 | $ 354 | 379
Percent Change (as a percent) | 1.60% |  | (6.40%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 132 | 132 | $ 249 | 286
Percent Change (as a percent) | (0.80%) |  | (13.00%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 47 | 43 | $ 105 | 92
Percent Change (as a percent) | 9.10% |  | 14.10% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 136 | 183 | $ 291 | 409
Percent Change (as a percent) | (25.60%) |  | (28.90%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 70 | 113 | $ 146 | 261
Percent Change (as a percent) | (38.30%) |  | (44.10%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 66 | 70 | $ 145 | 148
Percent Change (as a percent) | (5.00%) |  | (2.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER PULMONARY HYPERTENSION |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 312 | 368 | $ 614 | $ 742
Percent Change (as a percent) | (15.30%) |  |  | (17.30%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER PULMONARY HYPERTENSION | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 78 | 107 | $ 163 | $ 211
Percent Change (as a percent) | (27.70%) |  | (22.90%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER PULMONARY HYPERTENSION | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 234 | 260 | $ 451 | 531
Percent Change (as a percent) | (10.20%) |  | (15.00%) |
MEDICAL DEVICES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,288 | 6,489 | $ 10,220 | 12,948
Percent Change (as a percent) | (33.90%) |  | (21.10%) |
MEDICAL DEVICES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,862 | 3,083 | $ 4,760 | 6,192
Percent Change (as a percent) | (39.60%) |  | (23.10%) |
MEDICAL DEVICES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,426 | 3,406 | $ 5,460 | 6,756
Percent Change (as a percent) | (28.80%) |  | (19.20%) |
MEDICAL DEVICES | Interventional Solutions |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 590 | 750 | $ 1,317 | 1,482
Percent Change (as a percent) | (21.50%) |  | (11.20%) |
MEDICAL DEVICES | Interventional Solutions | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 255 | 366 | $ 620 | 709
Percent Change (as a percent) | (30.50%) |  | (12.60%) |
MEDICAL DEVICES | Interventional Solutions | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 335 | 385 | $ 697 | 774
Percent Change (as a percent) | (12.80%) |  | (9.90%) |
MEDICAL DEVICES | Orthopaedics |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,451 | 2,224 | $ 3,489 | 4,428
Percent Change (as a percent) | (34.70%) |  | (21.20%) |
MEDICAL DEVICES | Orthopaedics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 869 | 1,331 | $ 2,119 | 2,649
Percent Change (as a percent) | (34.70%) |  | (20.00%) |
MEDICAL DEVICES | Orthopaedics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 583 | 894 | $ 1,371 | 1,779
Percent Change (as a percent) | (34.80%) |  | (22.90%) |
MEDICAL DEVICES | Orthopaedics | HIPS |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 226 | 364 | $ 563 | 725
Percent Change (as a percent) | (37.80%) |  | (22.30%) |
MEDICAL DEVICES | Orthopaedics | HIPS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 137 | 216 | $ 343 | 429
Percent Change (as a percent) | (36.50%) |  | (20.10%) |
MEDICAL DEVICES | Orthopaedics | HIPS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 88 | 147 | $ 220 | 295
Percent Change (as a percent) | (39.80%) |  | (25.40%) |
MEDICAL DEVICES | Orthopaedics | KNEES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 174 | 372 | $ 517 | 741
Percent Change (as a percent) | (53.10%) |  | (30.10%) |
MEDICAL DEVICES | Orthopaedics | KNEES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 108 | 218 | $ 322 | 441
Percent Change (as a percent) | (50.50%) |  | (27.10%) |
MEDICAL DEVICES | Orthopaedics | KNEES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 66 | 153 | $ 196 | 299
Percent Change (as a percent) | (56.80%) |  | (34.60%) |
MEDICAL DEVICES | Orthopaedics | TRAUMA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 553 | 672 | $ 1,207 | 1,357
Percent Change (as a percent) | (17.80%) |  | (11.10%) |
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 354 | 407 | $ 761 | 824
Percent Change (as a percent) | (12.90%) |  | (7.60%) |
MEDICAL DEVICES | Orthopaedics | TRAUMA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 198 | 265 | $ 445 | 533
Percent Change (as a percent) | (25.20%) |  | (16.50%) |
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 499 | 818 | $ 1,202 | 1,606
Percent Change (as a percent) | (39.00%) |  | (25.10%) |
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 270 | 490 | $ 693 | 955
Percent Change (as a percent) | (45.00%) |  | (27.40%) |
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 230 | 328 | $ 510 | 651
Percent Change (as a percent) | (29.90%) |  | (21.70%) |
MEDICAL DEVICES | Surgery |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,551 | 2,353 | $ 3,651 | 4,748
Percent Change (as a percent) | (34.10%) |  | (23.10%) |
MEDICAL DEVICES | Surgery | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 490 | 926 | $ 1,334 | 1,927
Percent Change (as a percent) | (47.00%) |  | (30.80%) |
MEDICAL DEVICES | Surgery | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,060 | 1,427 | $ 2,317 | 2,821
Percent Change (as a percent) | (25.70%) |  | (17.90%) |
MEDICAL DEVICES | Surgery | ADVANCED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 775 | 1,029 | $ 1,723 | 2,009
Percent Change (as a percent) | (24.60%) |  | (14.20%) |
MEDICAL DEVICES | Surgery | ADVANCED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 277 | 396 | $ 658 | 800
Percent Change (as a percent) | (30.00%) |  | (17.70%) |
MEDICAL DEVICES | Surgery | ADVANCED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 498 | 633 | $ 1,065 | 1,209
Percent Change (as a percent) | (21.20%) |  | (11.90%) |
MEDICAL DEVICES | Surgery | GENERAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 775 | 1,325 | $ 1,928 | 2,739
Percent Change (as a percent) | (41.50%) |  | (29.60%) |
MEDICAL DEVICES | Surgery | GENERAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 213 | 530 | $ 676 | 1,127
Percent Change (as a percent) | (59.80%) |  | (40.00%) |
MEDICAL DEVICES | Surgery | GENERAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 562 | 794 | $ 1,252 | 1,612
Percent Change (as a percent) | (29.20%) |  | (22.40%) |
MEDICAL DEVICES | Vision |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 695 | 1,161 | $ 1,762 | 2,290
Percent Change (as a percent) | (40.10%) |  | (23.00%) |
MEDICAL DEVICES | Vision | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 248 | 461 | $ 687 | 907
Percent Change (as a percent) | (46.10%) |  | (24.20%) |
MEDICAL DEVICES | Vision | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 447 | 701 | $ 1,075 | 1,383
Percent Change (as a percent) | (36.10%) |  | (22.30%) |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 554 | 842 | $ 1,368 | 1,666
Percent Change (as a percent) | (34.10%) |  | (17.90%) |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 203 | 333 | $ 549 | 654
Percent Change (as a percent) | (39.00%) |  | (16.10%) |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 352 | 509 | $ 819 | 1,011
Percent Change (as a percent) | (30.90%) |  | (19.00%) |
MEDICAL DEVICES | Vision | SURGICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 141 | 319 | $ 394 | 624
Percent Change (as a percent) | (55.80%) |  | (36.80%) |
MEDICAL DEVICES | Vision | SURGICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 45 | 128 | $ 138 | 253
Percent Change (as a percent) | (64.60%) |  | (45.30%) |
MEDICAL DEVICES | Vision | SURGICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 96 | $ 191 | $ 256 | $ 371
Percent Change (as a percent) | (49.90%) |  | (31.00%) |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ERLEADAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_VELCADEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |